Maple Tree Capital, an investment management company, released its Q3 2025 investor letter. A copy of the letter can be ...

The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, has consistently positioned technology and clinical ...

In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $33.05, marking a -3.09% move from the previous day. This change lagged the S&P 500's 0.14% loss on the day. Elsewhere, the Dow ...

Hims & Hers Health (NYSE: HIMS) went public in January 2021 through a SPAC merger, positioning itself as a multi-specialty ...

Hims & Hers wants to launch its own weight loss program with GLP-1s like Ozempic. CEO Andrew Dudum worries about three challenges to the new market.

Hims & Hers compounded GLP-1 — the same ingredient as Ozempic — will be priced at $200 a month. Investors are loving the announcement.

A short squeeze occurs when a stock's price rises unexpectedly, forcing short sellers (who are now losing money) to ...

The financial outlook for telehealth provider Hims & Hers is showing signs of strain. Despite posting a robust 49% year-over-year revenue increase to $599 million for Q3 2025, underlying business ...

Digital health and wellness company Hims & Hers is investing more than $200 million to expand its operations in New Albany ...

Hims & Hers Health (NYSE: HIMS), a telehealth platform, has recently announced its Q1 financial results, showing notable year-over-year growth. The company reported adjusted earnings per share of ...

In recent years, we've seen a broader dialogue around the benefits of creating affordable, accessible health care for all—and whether or not it's actually achievable. While there's still plenty of ...